CCL2 and type 2 diabetes mellitus: It was demonstrated that taraxerol, present in the F2 fraction, was involved in reversing insulin resistance induced by dexamethasone [45], and it was able to restore renal physiology in a rodent model of type 2 diabetes by lowering blood glucose and reducing the secretion of pro-inflammatory cytokines such as MCP-1, IL-1β, IL-6, and TNF-α [46].